Search results for "Malignancy"

showing 10 items of 274 documents

Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice

2013

Epithelial ovarian cancer (EOC) is the sixth most common malignancy in women. Ovarian tumors consist of several clinical and pathological entities that share an anatomic site. The gold standard treatment, both in front-line and in adjuvant setting, is represented by carboplatin/paclitaxel combination. Conversely, the second-line treatment is not well defined. The response to platinum is the major prognostic factor for survival. In this review we discuss the current views on platinum-refractory/resistant patient treatment only, which includes patients progressing or relapsing within 6 months from the last platinum-based course. Concerning this subgroup, the activity of several conventional d…

GynecologyOncologymedicine.medical_specialtyendocrine system diseasesBevacizumabtarget therapybusiness.industrymedicine.medical_treatmentGold standardbevacizumabmedicine.diseaseMalignancyCarboplatinchemistry.chemical_compoundovarian cancerPaclitaxelchemistryInternal medicinemedicineplatinumbusinessOvarian cancerPathologicalAdjuvantmedicine.drugJournal of Cancer Therapy
researchProduct

Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review.

2011

Human papillomavirus (HPV) in oral carcinoma (OSCC) and potentially malignant disorders (OPMD) is controversial. The primary aim was to calculate pooled risk estimates for the association of HPV with OSCC and OPMD when compared with healthy oral mucosa as controls. We also examined the effects of sampling techniques on HPV detection rates. Methods: Systematic review was performed using PubMed (January 1966-September 2010) and EMBASE (January 1990-September 2010). Eligible studies included randomized controlled, cohort and cross-sectional studies. Pooled data were analysed by calculating odds ratios, using a random effects model. Risk of bias was based on characteristics of study group, appr…

HPVprecancerAlphapapillomavirusmeta-analysiCohort StudiespremalignancyBiasSettore MED/28 - Malattie OdontostomatologicheRisk Factorscase–controlHumansbiopsyhumanProspective StudiesRandomized Controlled Trials as Topiclichen planuerythroplakiaadultPapillomavirus Infectionsoral cancerCell Transformation ViralControl GroupsCross-Sectional StudiesleukoplakiacytologyMouth NeoplasmsPrecancerous ConditionsOral diseases
researchProduct

Diagnostic Performance of Multiparametric Magnetic Resonance Imaging and Fusion Targeted Biopsy to Detect Significant Prostate Cancer

2017

Background/aim Multiparametric magnetic resonance imaging combined with ultrasound-fusion-targeted biopsy of the prostate intends to increase diagnostic precision, which has to be clarified. Patients and methods We performed multiparametric magnetic resonance imaging followed by ultrasound-fusion-guided perineal biopsy in 99 male patients with elevated prostate-specific-antigen and previous negative standard biopsy-procedures. Results In 33/99 patients (33%) no malignancy could be confirmed by histopathology. Low-grade carcinomas (Gleason-Score 6+7a) were found in 42/66 (64%) and high-grade carcinomas (Gleason-Score ≥7b) in 24/66 (36%) men. A high-grade carcinoma corresponded to PI-RADS 4 o…

Image-Guided BiopsyMaleCancer Researchmedicine.medical_specialty030232 urology & nephrologyMalignancySensitivity and Specificity03 medical and health sciencesProstate cancer0302 clinical medicineProstateBiopsymedicineCarcinomaHumansEndoscopic Ultrasound-Guided Fine Needle AspirationMultiparametric Magnetic Resonance ImagingAgedAged 80 and overmedicine.diagnostic_testbusiness.industryProstateProstatic NeoplasmsReproducibility of ResultsMagnetic resonance imagingGeneral MedicineMiddle AgedProstate-Specific Antigenmedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureOncology030220 oncology & carcinogenesisHistopathologyRadiologyNeoplasm GradingbusinessAnticancer Research
researchProduct

Angiomyolipome der Nieren bei Morbus Bourneville-Pringle

1984

Three cases with renal angiomyolipoma in Bourneville's disease are reported. In two patients advanced renal insufficiency developed, one being treated by chronic intermittent hemodialysis. In the third patient rupture of angiomyolipoma with severe retroperitoneal bleeding occurred. In one patient, tumorous enlargement initially was diagnosed only in the right kidney and preceded angiomyolipoma of the left kidney for several years. In this patient nephrectomy was performed because malignancy was assumed before diagnosis of Bourneville's disease was established. Occasionally, histology may suggest sarcomatous changes. However, the absence of distant metastasis and the overall long survival of…

Kidneymedicine.medical_specialtyAngiomyolipomabusiness.industrymedicine.medical_treatmentHistologyGeneral MedicineDiseasemedicine.diseaseMalignancyNephrectomyTuberous sclerosismedicine.anatomical_structureDrug DiscoveryParenchymamedicineMolecular MedicineRadiologybusinessGenetics (clinical)Klinische Wochenschrift
researchProduct

Laparoscopic adrenalectomy for large adrenal masses: Single team experience

2014

Abstract Introduction Laparoscopic adrenalectomy is today considered the standard treatment for benign small adrenal tumors. An open question is the use of laparoscopy for large adrenal masses because of technical limitations and increased risk of malignancy. In this study we report our experience in laparoscopic adrenalectomy for adrenal masses larger than 6 cm. Methods Between January 2010 and December 2013 we performed 41 laparoscopic adrenalectomy. Fourteen of 41 patients (34,1%) were submitted to laparoscopic adrenalectomy for lesion >6 cm in size. All patients were submitted routinely to radiological and hormonal tests to indentify tumors characteristics. Results The patients treated …

Laparoscopic surgeryAdenomaAdultMalemedicine.medical_specialtymedicine.medical_treatmentOperative TimeAdrenal Gland NeoplasmsLaparoscopic adrenalectomyPheochromocytomaLaparoscopic surgeryMalignancyLesionMyelolipomamedicineHumansLaparoscopyAgedmedicine.diagnostic_testLaparoscopic adrenalectomybusiness.industryAdrenalectomyStandard treatmentLarge adrenal tumorsAdrenalectomyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTumor BurdenSettore MED/18 - Chirurgia GeneraleTreatment Outcomelaparoscopic adrenalectomy; laparoscopyRadiological weaponFemaleLaparoscopySurgerymedicine.symptombusinessFollow-Up StudiesInternational Journal of Surgery
researchProduct

Recurrence of a laryngeal spindle cell sarcoma with a transformation into a higher grade of malignancy.

2009

Primary malignant mesenchymal neoplasms of the larynx are rare. Sarcomas of the larynx account for <1% of all malignant laryngeal mesenchymal neoplasms. This report examines a case of a recurring laryngeal, initial benign-appearing mesenchymal tumour, which first changed its clinical phenotype without any histological signs of malignancy and later also its histological appearance with signs of malignancy. Finally, it even underwent a transformation into a higher grade of malignancy. In addition to this, the difficulties of allocating this tumour to the correct sarcoma subentity are shown.

LarynxMalePathologymedicine.medical_specialtybusiness.industryMesenchymal stem cellSarcomaGeneral Medicinemedicine.diseaseMalignancystomatognathic diseasesmedicine.anatomical_structureFatal OutcomeOtorhinolaryngologyMedicineHumansSurgeryRadiotherapy AdjuvantSpindle cell sarcomaSarcomaNeoplasm Recurrence LocalbusinessClinical phenotypeLaryngeal NeoplasmsAgedAuris, nasus, larynx
researchProduct

The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.

2019

BACKGROUND: Although uterine leiomyomas and leiomyosarcomas are considered biologically unrelated tumors, they share morphologic and histologic characteristics that complicate their differential diagnosis. The long-term therapeutic option for leiomyoma is laparoscopic myomectomy with morcellation, particularly for patients who wish to preserve their fertility. However, because of the potential dissemination of undiagnosed or hidden leiomyosarcoma from morcellation, there is a need to develop a preoperative assessment of malignancy risk. OBJECTIVE: Through an integrated comparative genomic and transcriptomic analysis, we aim to identify differential genetic targets in leiomyomas vs leiomyosa…

LeiomyosarcomaAdultLeiomyosarcomaDNA Copy Number Variationsmedicine.disease_causeMalignancyPolymorphism Single NucleotideDNA sequencinggenomic/transcriptomic profileuterine leiomyosarcomaDiagnosis Differential03 medical and health sciences0302 clinical medicineGene DuplicationmedicineHumans030212 general & internal medicineCopy-number variationGeneAgedMutation030219 obstetrics & reproductive medicineuterine leiomyomaLeiomyomabusiness.industrySequence Analysis RNAGene Expression ProfilingObstetrics and GynecologyHigh-Throughput Nucleotide SequencingGenomicsSequence Analysis DNAMiddle Agedmedicine.diseaseBRCA2body regionsLeiomyomaUterine NeoplasmsCancer researchFGFR4FemaleDifferential diagnosisGene FusionbusinessROS1DNA/RNA sequencingGene DeletionAmerican journal of obstetrics and gynecology
researchProduct

Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas.

2016

The diagnosis of malignancy in cutaneous and subcutaneous smooth muscle tumors is based on subtle criteria. Therefore, any ancillary technique useful in this differential diagnosis is always welcome. In this report, we study the immunoexpression of p53 in 19 malignant smooth muscle tumors of the skin (15 cutaneous leiomyosarcomas, 2 subcutaneous leiomyosarcomas, and 2 cutaneous metastases of leiomyosarcoma), as well as in 1 leiomyoma with cellular atypia, therefore complementing a previous study on p53 immunoexpression in leiomyomas of the skin. The p53 staining was positive in 12 (63.16%) of 19 leiomyosarcomas. Percentages of immunostaining in the positive cases varied from 2% to 95%. Ten …

LeiomyosarcomaAdultLeiomyosarcomaMalePathologymedicine.medical_specialtySkin NeoplasmsMalignancyPathology and Forensic MedicineDiagnosis Differential030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineHumansCutaneous leiomyosarcomaSmooth Muscle TumorAgedAged 80 and overLeiomyomabusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryStainingbody regionsLeiomyoma030220 oncology & carcinogenesisSmooth Muscle TumorUterine NeoplasmsFemaleDifferential diagnosisTumor Suppressor Protein p53businessImmunostainingAnnals of diagnostic pathology
researchProduct

Leukemia Cutis: A Report of 17 Cases and a Review of the Literature

2016

Dermatologic manifestations of leukemia can be both specific and nonspecific (e.g., opportunistic infections, purpura and ecchymosis, Sweet syndrome). Leukemia cutis refers to the infiltration of the skin with neoplastic leukocytes and its early diagnosis has important prognostic implications. We report on 17 cases of leukemia cutis seen in our department between 1994 and 2014 and describe the characteristics of the patients (age, sex, medical history), the morphology of the lesions, and associations with systemic disease. Most of the patients were male and the most common associated malignancy was acute myeloid leukemia. The most frequent dermatologic manifestations were nodules or erythem…

Leukemic InfiltrationPathologymedicine.medical_specialtyHistologybusiness.industrySweet SyndromeEcchymosisMyeloid leukemiaLeukemia cutisDermatologymedicine.diseaseMalignancyDermatologyPathology and Forensic Medicine030207 dermatology & venereal diseases03 medical and health sciencesLeukemia0302 clinical medicinehemic and lymphatic diseasesmedicineMedical history030212 general & internal medicinemedicine.symptombusinessActas Dermo-Sifiliográficas (English Edition)
researchProduct

Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53

2020

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic malignancy. Approximately 85% of pancreatic cancers are classified as PDACs. The survival of PDAC patients is very poor and only 5–10% of patients survive 5 years after diagnosis. Mutations at the KRAS and TP53 gene are frequently observed in PDAC patients. The PANC-28 cell line lacks wild-type (WT) TP53. In the following study, we have investigated the effects of restoration of WT TP53 activity on the sensitivity of PANC-28 pancreatic cancer cells to various drugs which are used to treat PDAC patients as well as other cancer patients. In addition, we have examined the effects of signal transduction inhibitors which tar…

Male0301 basic medicineDrugCancer ResearchmiRsendocrine system diseasesmedia_common.quotation_subjectSignal transduction inhibitorsTargeted therapeuticAntineoplastic AgentsMalignancymedicine.disease_causeProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineChloroquinePancreatic cancerGeneticsmedicineHumansTP53Molecular BiologyneoplasmsSignal transduction inhibitorTargeted therapeuticsCell Proliferationmedia_commontarget therapeuticsCell growthbusiness.industryCancermedicine.diseasedigestive system diseasesMetforminPancreatic Neoplasms030104 developmental biology030220 oncology & carcinogenesisDietary SupplementsMutationCancer researchmiRs.Molecular MedicineFemaleKRASTumor Suppressor Protein p53businessSignal Transductionmedicine.drugDrug sensitivity
researchProduct